ROR1 is a very promising target for the treatment of CLL, particularly in conjunction with venetoclax treatment, however, some therapeutical approaches are still in early stages of development, many drugs are tested to determine their safety and efficacy and further studies are needed to determine if CAR T cell therapy, small molecules or monoclonal antibodies are a safe and efficient option in CLL management. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.